de Heus Roel, Mulder Eduard J H, Derks Jan B, Kurver Piet H J, van Wolfswinkel Leo, Visser Gerard H A
Department of Perinatology & Gynecology, University Medical Centre Utrecht, The Netherlands.
Eur J Obstet Gynecol Reprod Biol. 2008 Aug;139(2):139-45. doi: 10.1016/j.ejogrb.2008.01.001. Epub 2008 Mar 7.
To study the effects of the tocolytics atosiban and ritodrine in term labour.
Women in term labour, requiring acute tocolysis, were prospectively randomized for treatment with either atosiban i.v. (n=70) or ritodrine i.v. (n=70). There were three indications for acute tocolysis: (1) fetal distress followed by continuation of labour, (2) fetal distress followed by emergency caesarean section (CS), and (3) arrest of contractions in women waiting for a secondary CS in the absence of fetal distress. Primary endpoints were maternal blood pressure (MBP) and maternal heart rate (MHR). Secondary endpoints were intra-uterine pressure, fetal heart rate (FHR), 5'-Apgar score and umbilical arterial pH.
Baseline characteristics did not differ between the study groups. The ritodrine group showed a significant rise in MHR (p<0.001), MHR remained unaltered in the atosiban group (p=0.31). No significant changes occurred in systolic and diastolic BP in either group. FHR rose by a maximum of 11.6 bpm (8.5%) in the ritodrine group (p<0.001) compared to a rise of 4.9 bpm (4.8%) in the atosiban group (p=0.27). No differences were found in blood loss and fetal outcome. Compared to baseline, uterine pressure was reduced by a maximum of 55% (p<0.001) after ritodrine administration, compared to a maximal reduction of 54% (p<0.001) after atosiban administration. These effects did not differ between the two treatment groups.
Considering the maternal effects, our results suggest a possible role for atosiban bolus in acute tocolysis in term labour.
研究宫缩抑制剂阿托西班和利托君在足月分娩中的作用。
对需要紧急抑制宫缩的足月分娩妇女进行前瞻性随机分组,分别静脉注射阿托西班(n = 70)或利托君(n = 70)。紧急抑制宫缩有三个指征:(1)胎儿窘迫后继续分娩;(2)胎儿窘迫后行急诊剖宫产;(3)在无胎儿窘迫的情况下,等待二次剖宫产的妇女宫缩停止。主要终点指标为产妇血压(MBP)和产妇心率(MHR)。次要终点指标为子宫内压、胎儿心率(FHR)、5分钟阿氏评分和脐动脉pH值。
研究组间基线特征无差异。利托君组MHR显著升高(p<0.001),阿托西班组MHR无变化(p = 0.31)。两组收缩压和舒张压均无显著变化。利托君组FHR最多升高11.6次/分(8.5%)(p<0.001),阿托西班组升高4.9次/分(4.8%)(p = 0.27)。两组在失血量和胎儿结局方面未发现差异。与基线相比,注射利托君后宫内压最大降低55%(p<0.001),注射阿托西班后宫内压最大降低54%(p<0.001)。两种治疗组之间的这些效果无差异。
考虑到对产妇的影响,我们的结果表明阿托西班推注在足月分娩急性抑制宫缩中可能有作用。